β-Adrenergic signalling mediates the positive inotropic effect of catecholamines on cardiomyocytes, mainly through cAMP generation and subsequent activation of PKA (protein kinase A). Given the large diversity of PKA targets within cardiac cells, a precisely regulated and confined activity of such signalling pathways is essential for the specificity of response. PDEs (phosphodiesterases) constitute the only cAMP-degrading mechanism and are expressed in the cardiomyocyte in at least 5 family variants. Each PDE family is characterized by unique functional properties and contributes to a cAMP-degrading system enabling the modulation of PKA activity in a stimulus-dependent fashion.
Introduction
The force and frequency of cardiomyocyte contraction is continuously tuned by a number of signals conveyed from the bloodstream, the neighbouring cells and the cardiac nerve endings. Many such signals exert their function through the modulation of ACs (adenylate cyclases) that synthesize cAMP controlling PKA (protein kinase A) activation. Intriguingly, the cAMP/PKA pathway can carry messages that have the potential to influence cardiomyocyte metabolism, growth and death, hence the need for this signalling pathway to be specifically regulated [1] . More than 20 years ago, it was observed that prostaglandin E 1 and the β-AR (β-adrenoceptor) agonist isoprenaline, which affect cardiomyocyte function differently, increase cAMP in distinct cellular compartments [2] . More recently, the discovery that PKA, the main target of cAMP, can be tethered to specific subcellular structures through binding to AKAPs (A-kinase-anchoring proteins) fostered the idea of spatial compartmentation of cAMP signalling [3] . According to this general and now well-accepted concept, a specific type of membrane receptor can activate a pool of PKA located at defined subcellular sites and in close proximity to a limited number of targets, thus ensuring specificity of response. Such a model implies the local control of PKA activity through the generation of confined gradients of high [cAMP] at the site where subsets of PKA are localized. The existence of such cAMP microdomains was proved directly by using fluorescent biosensors capable of detecting changes in the secondmessenger concentration with high spatial resolution [4, 5] .
PDEs (phosphodiesterases) provide the only route to degrade cAMP and are therefore crucial for the generation of intracellular gradients of this second messenger [6] . As cAMP diffuses freely in the cytoplasm, in the absence of PDEs, its concentration would rapidly equalize and uniformly fill the entire cell [7] . Throughout the species, PDEs are highly conserved and exist in approx. 40 variants; interestingly, the same cell type can simultaneously express a variety of PDE isoforms, suggesting that the various families of PDE can have different functions [6] .
The PDE system regulating the β-AR response in rat cardiomyocytes
NRVMs (neonatal rat ventricular myocytes) co-express at least five families of PDE. In the whole cell, PDE4 and PDE3 account for the majority of cAMP degradation, while PDE1 and PDE2 degrade only a minor fraction of total cAMP [8] . Real-time cAMP imaging experiments [8] , as well as experiments using a channel-based reporter for cAMP [9] , revealed that PDE4 and PDE2 co-operate in regulating cAMP dynamics upon catecholamine stimulation. In addition, PDE5 indirectly participates in the control of cAMP concentration by modulating the intracellular level of cGMP, thus influencing the activity of PDE3 (which is cGMP-activated) and PDE2 (which is cGMP-inhibited).
PDE4 is the major family expressed in NRVMs [8] . Degradation of cAMP by PDE4s is crucial in the regulation of cAMP levels following β-AR activation. At least two models describing PDE4 function have been proposed, using multiple experimental approaches. (i) PDE4 enzymes placed in proximity to the site of cAMP synthesis, by virtue of their localization can restrict cAMP diffusion throughout the cell [10] and generate discrete microdomains of high cAMP. This mechanism would allow the activation of spatially-defined pools of PKA, leading to the control of a defined group of targets, contributing to signalling specificity. (ii) PDE4 can interact directly with the scaffold proteins that anchor PKA at distant locations from the source of cAMP. PDE4s anchored to AKAPs also localizes the cAMP hydrolytic activity in close proximity to PKA. In such local microenvironments, the probability that cAMP interacts with PKA is reduced by the competing degradation activity of PDE4 [10] . In isolated adult cardiomyocytes, the PDE4D3 isoform was found to participate in a macromolecular complex including RyR2 (ryanodine receptor 2) and PKA [11] . Thanks to this localization, PDE4D3 specifically regulates the PKA-mediated phosphorylation of the RyR that modulates Ca 2+ release from the SR (sarcoplasmic reticulum) [11] . The range of activity of PDE4D3 is thus restricted to a very narrow domain. In fact, mice lacking PDE4D3 had globally intact cAMP signalling, but featured a selective impairment of the regulation of PKA-dependent Ca 2+ release from the SR [11] . PDE4 can re-distribute in the cell compartments, adding to the complexity of the dynamics of cAMP degradation. PDE4D3 and PDE4D5 form stable complexes with the signalling protein β-arrestin, which are found in the cytoplasm of resting cells [12] . Catecholamines trigger the translocation of the PDE4-β-arrestin complex to the membrane domains where activated β-ARs and ACs reside. In so doing, cAMP-degrading enzymes accumulate close to the site of cAMP synthesis. Displacement of the PDE4 from β-arrestin impairs the cAMP degradation subsequent to β-AR activation, enhancing, as a consequence, the agonist-induced PKA activity at the plasma membrane [12] .
PDE2 is expressed at very low concentrations in neonatal rat cardiomyocytes, and its activity contributes to the degradation of less than 3% of the total cAMP [13] . By performing real-time cAMP imaging, we found, accordingly, that PDE2 had a negligible role in controlling cAMP concentration in the resting cell. However, in the presence of β-AR agonists, PDE2 inhibition released a large amount of cAMP, resulting in a Ca 2+ -driven increase in contractility [13] . This suggests that the pool of ACs activated by β-AR and PDE2 are functionally coupled, and that the latter is engaged specifically in the degradation of cAMP synthesized by the former. Moreover, as PDE2 is allosterically activated by cGMP, agents that elevate intracellular cGMP blunted the cAMP increase elicited by β-AR stimulation; cGMP also decreased the Ca 2+ -dependent contractile response to catecholamines [13] . PDE2 therefore constitutes a signalling 'node' that integrates the input of two distinct cyclic-nucleotide-dependent pathways, regulating, in turn, a Ca 2+ -dependent effect such as contraction.
PDE5 is expressed in the heart; however, its role in regulating myocardial contractility has been questioned [14] . As PDE5 is a cGMP-dependent PDE and is unable to hydrolyse cAMP, it does not affect cAMP levels and activation of PKA directly. However, PDE5 inhibition counteracts the cAMPmediated inotropic effect of catecholamines. The molecular mechanism underlying the effect of PDE5 inhibition on contractility has not been elucidated, but at least two potential mechanisms have been suggested: (i) the increase in cGMP levels following PDE5 inhibition leads to activation of protein kinase G, which phosphorylates troponin I, depressing myofilament calcium sensitivity; and (ii) the rise in cGMP levels secondary to PDE5 inhibition leads to PDE2 activation, increased cAMP degradation and blunting of the PKAmediated inotropy. Interestingly, PDE5 has been found to localize within the same intracellular compartments as PDE2 [13, 14] . It is therefore tempting to speculate that PDE5 inhibition releases enough cGMP locally to activate PDE2, resulting in decreased cAMP concentrations in response to β-AR stimulation. In support of this hypothesis, delocalization of PDE5 from the Z-bands was accompanied by a reduced effect of PDE5 inhibitors on contractility [14] .
Conclusions
Thanks to the multiple mechanisms of regulation and localization, the PDE system actively modulates cAMP and PKA in a stimulus-dependent fashion. Upon stimulation of one receptor type, a unique combination of PDEs functionally coupled to the receptor is engaged in restricting the access of cAMP to specific pools of PKA, activating a limited number of targets. In physiological conditions, such a system of cAMP degradation is modulated by the presence of stimuli that activate other signalling pathways. The cross-talk with other signalling pathways increases the complexity of the cAMP-PKA-PDE interactions and ensures a higher degree of specificity to cAMP-dependent signalling. Pathological events affecting the expression level, the activity or the localization of PDEs may lead to loss of fidelity of cAMP signalling, affecting the fine regulation of cAMP dynamics. Alterations in cAMP signalling resulting in inappropriate activity of PKA may be involved in the development of cardiomyocyte dysfunction leading to heart failure.
